166 related articles for article (PubMed ID: 35304261)
21. Prognostic factors in uveal melanoma.
Singh AD; Shields CL; Shields JA
Melanoma Res; 2001 Jun; 11(3):255-63. PubMed ID: 11468514
[TBL] [Abstract][Full Text] [Related]
22. Clinicopathological Characteristics and Prognosis for Survival after Enucleation of Uveal Melanoma in Chinese Patients: Long-term Follow-up.
Yue H; Qian J; Yuan Y; Zhang R; Bi Y; Meng F; Xuan Y
Curr Eye Res; 2017 May; 42(5):759-765. PubMed ID: 27911584
[TBL] [Abstract][Full Text] [Related]
23. Prognosis of Mucosal, Uveal, Acral, Nonacral Cutaneous, and Unknown Primary Melanoma From the Time of First Metastasis.
Kuk D; Shoushtari AN; Barker CA; Panageas KS; Munhoz RR; Momtaz P; Ariyan CE; Brady MS; Coit DG; Bogatch K; Callahan MK; Wolchok JD; Carvajal RD; Postow MA
Oncologist; 2016 Jul; 21(7):848-54. PubMed ID: 27286787
[TBL] [Abstract][Full Text] [Related]
24. Survival in patients with uveal melanoma in Europe.
Virgili G; Gatta G; Ciccolallo L; Capocaccia R; Biggeri A; Crocetti E; Lutz JM; Paci E;
Arch Ophthalmol; 2008 Oct; 126(10):1413-8. PubMed ID: 18852420
[TBL] [Abstract][Full Text] [Related]
25. Forty-year prognosis after plaque brachytherapy of uveal melanoma.
Stålhammar G
Sci Rep; 2020 Jul; 10(1):11297. PubMed ID: 32647177
[TBL] [Abstract][Full Text] [Related]
26. Uveal melanoma in young patients.
Pogrzebielski A; Orłowska-Heitzman J; Romanowska-Dixon B
Graefes Arch Clin Exp Ophthalmol; 2006 Dec; 244(12):1646-9. PubMed ID: 16636835
[TBL] [Abstract][Full Text] [Related]
27. [Immunotherapy of uveal melanoma: vaccination against cancer. Multicenter adjuvant phase 3 vaccination study using dendritic cells laden with tumor RNA for large newly diagnosed uveal melanoma].
Schuler-Thurner B; Bartz-Schmidt KU; Bornfeld N; Cursiefen C; Fuisting B; Grisanti S; Heindl LM; Holbach L; Keserü M; Knorr H; Koch K; Kruse F; Meiller R; Metz C; Meyer-ter-Vehn T; Much M; Reinsberg M; Schliep S; Seitz B; Schuler G; Süsskind D; Viestenz A; Wagenfeld L; Zeschnigk M
Ophthalmologe; 2015 Dec; 112(12):1017-21. PubMed ID: 26602097
[TBL] [Abstract][Full Text] [Related]
28. [Uveal melanoma: clinical characteristics, treatment and survival in a series of 500 patients].
Vicente N; Saornil MA; García-Álvarez C; Almaraz A; Alonso Martínez P; Frutos-Baraja JM; López-Lara F
Arch Soc Esp Oftalmol; 2013 Nov; 88(11):433-8. PubMed ID: 24157321
[TBL] [Abstract][Full Text] [Related]
29. Uveal Melanoma UK National Guidelines.
Nathan P; Cohen V; Coupland S; Curtis K; Damato B; Evans J; Fenwick S; Kirkpatrick L; Li O; Marshall E; McGuirk K; Ottensmeier C; Pearce N; Salvi S; Stedman B; Szlosarek P; Turnbull N;
Eur J Cancer; 2015 Nov; 51(16):2404-12. PubMed ID: 26278648
[TBL] [Abstract][Full Text] [Related]
30. Uveal melanoma: Current evidence on prognosis, treatment and potential developments.
Gelmi MC; Jager MJ
Asia Pac J Ophthalmol (Phila); 2024; 13(2):100060. PubMed ID: 38641203
[TBL] [Abstract][Full Text] [Related]
31. Prognostic factors of liver metastases from uveal melanoma.
Kodjikian L; Grange JD; Baldo S; Baillif S; Garweg JG; Rivoire M
Graefes Arch Clin Exp Ophthalmol; 2005 Oct; 243(10):985-93. PubMed ID: 15891893
[TBL] [Abstract][Full Text] [Related]
32. Uveal melanoma in the first 4 decades of life.
Sagus M; Bedikian AY
South Med J; 2015 Mar; 108(3):158-63. PubMed ID: 25772049
[TBL] [Abstract][Full Text] [Related]
33. Sex Disparity in Survival of Patients With Uveal Melanoma: Better Survival Rates in Women Than in Men in South Korea.
Park SJ; Oh CM; Yeon B; Cho H; Park KH
Invest Ophthalmol Vis Sci; 2017 Mar; 58(3):1909-1915. PubMed ID: 28362882
[TBL] [Abstract][Full Text] [Related]
34. [Ocular retention in patients with uveal melanoma managed by a multimodality approach].
García-Alvarez C; Muiños Y; Saornil MA; Almaraz A; López-Lara F; Frutos JM; Muñoz MF
Arch Soc Esp Oftalmol; 2009 Mar; 84(3):145-9. PubMed ID: 19340720
[TBL] [Abstract][Full Text] [Related]
35. Posterior uveal melanoma. The Swedish perspective.
Seregard S
Acta Ophthalmol Scand; 1996 Aug; 74(4):315-29. PubMed ID: 8883543
[TBL] [Abstract][Full Text] [Related]
36. [Ciliary body melanomas. Survival and prognostic aspects after brachytherapy or proton therapy].
Gambrelle J; Kodjikian L; Rouberol F; Donate D; Duquesne N; Jean-Louis B; Chauvel P; Gérard JP; Romestaing P; Grange JD
J Fr Ophtalmol; 2004 Jan; 27(1):40-7. PubMed ID: 14968076
[TBL] [Abstract][Full Text] [Related]
37. Uveal melanoma: estimating prognosis.
Kaliki S; Shields CL; Shields JA
Indian J Ophthalmol; 2015 Feb; 63(2):93-102. PubMed ID: 25827538
[TBL] [Abstract][Full Text] [Related]
38. Adjuvant Sunitinib in High-Risk Patients with Uveal Melanoma: Comparison with Institutional Controls.
Valsecchi ME; Orloff M; Sato R; Chervoneva I; Shields CL; Shields JA; Mastrangelo MJ; Sato T
Ophthalmology; 2018 Feb; 125(2):210-217. PubMed ID: 28935400
[TBL] [Abstract][Full Text] [Related]
39. No differences in the long-term prognosis of iris and choroidal melanomas when adjusting for tumor thickness and diameter.
Sabazade S; Herrspiegel C; Gill V; Stålhammar G
BMC Cancer; 2021 Nov; 21(1):1270. PubMed ID: 34819035
[TBL] [Abstract][Full Text] [Related]
40. Clinical and histopathological features of choroidal melanoma-related enucleated eyes in a Spanish tertiary hospital.
García Tirado A; Asencio Durán M; Berjón A; Ruiz Bravo-Burguillos E; Peralta Calvo J
Arch Soc Esp Oftalmol (Engl Ed); 2019 May; 94(5):225-231. PubMed ID: 30904338
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
